2023-11-24 05:00:04
Scientists at Beth Israel Deaconess Medical Center have announced a major breakthrough in the fight once morest Parkinson’s disease. By inhibiting a specific enzyme called USP30, dopamine-producing neurons usually lost during disease progression (Disease is an alteration of the functions or health of a living organism, animal, etc.), were protected in a mouse model.
Image d’illustration Pixabay
This discovery opens up new therapeutic perspectives to slow down or even prevent the progression of Parkinson’s. The results of this study, published in Nature Communications, reveal the hope of developing innovative treatments for the 10 million people worldwide affected by this neurodegenerative disease.
Professor David K. Simon, director of the Parkinson’s Disease and Movement Disorders Center at BIDMC, led this research. According to him, these significant results suggest that reducing the activity of the enzyme USP30 might have beneficial effects in slowing the progression of Parkinson’s.
Indeed, the study demonstrates that the USP30 enzyme plays a crucial role in the degeneration of dopamine-producing cells (Dopamine is a neurotransmitter belonging to catecholamines and therefore comes from acid…). And by blocking this enzyme, researchers observed an increase in the elimination of damaged mitochondria, essential elements for health. cells. They now aspire to understand the origins of Parkinson’s disease, with the aim of one day being able to slow down or even prevent its progression in patients.
These encouraging results open the way to new trials to evaluate the potential of this promising therapeutic approach. Reducing the USP30 enzyme might well be the key to transforming the landscape of treatments once morest Parkinson’s.
1700808865
#enzyme #key #progression #Parkinsons
